ImmuPharma (LON:IMM)‘s stock had its “buy” rating restated by equities research analysts at Northland Securities in a research note issued to investors on Friday. They presently have a GBX 181 ($2.50) price target on the stock. Northland Securities’ target price would suggest a potential upside of 44.22% from the company’s previous close.
Separately, FinnCap reaffirmed a “buy” rating and issued a GBX 237 ($3.27) price target on shares of ImmuPharma in a research report on Thursday, December 21st.
ImmuPharma (LON:IMM) opened at GBX 125.50 ($1.73) on Friday. The stock has a market capitalization of $174.33 and a PE ratio of -3,137.50. ImmuPharma has a 52-week low of GBX 44 ($0.61) and a 52-week high of GBX 193.74 ($2.68).
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.